CLINICAL TRIALS PROFILE FOR MDP-BRACCO

All Clinical Trials for Mdp-bracco

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00590070 ↗	THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction	Completed	Catholic University of the Sacred Heart	Phase 2/Phase 3	2008-01-01	The occurrence of no-reflow phenomenon after recanalization of the infarct related artery in acute myocardial infarction is described in up to 40% of cases. This event is associated with a worse prognosis at follow up and an unfavourable left ventricular remodelling . Two main pathogenetic mechanisms cause no-reflow: distal embolization and ischemia-reperfusion injury. Due to the multifactorial pathogenesis of no-reflow during acute MI a combined mechanic and pharmacologic approach is believed to offer a better solution for achieving optimal microvascular reperfusion. Thus, in this randomized study we will assess the effect of nitroprusside or adenosine in adjunct to current best therapy (thrombus aspiration and IIb-IIIa antagonists) for ST elevation MI using ST segment resolution on standard 12 leads ECG as primary endpoint of myocardial reperfusion.
NCT00685477 ↗	Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying	Completed	Johns Hopkins University	N/A	2008-05-01	This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.
NCT00685477 ↗	Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying	Completed	Memorial Health University Medical Center	N/A	2008-05-01	This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.
NCT00685477 ↗	Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying	Completed	Penn State University	N/A	2008-05-01	This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.
NCT00685477 ↗	Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying	Completed	Temple University	N/A	2008-05-01	This is a clinical research study to establish normal values for the infusion of a synthetic form of the hormone cholecystokinin(CCK-8) for gallbladder emptying. Cholecystokinin is released from the small bowel to stimulate the pancreas and gallbladder to help digest and absorb food. Some people have gallbladder problems and need to be tested with the synthetic cholecystokinin ( Kinevac®, Bracco Diagnostics, Inc.). The aim of this study is to find out how differing amounts and intravenous infusion times of CCK-8 affect gallbladder emptying. The findings in normal subjects will be used to establish normal values that can then be compared with patients with suspected gallbladder disease.

Clinical Trial Conditions for Mdp-bracco

Condition Name

Condition Name for Mdp-bracco
Intervention	Trials
Early Primary Breast Cancer	1
Post Operative Pain	1
Healthy	1
Prostate Cancer	1

Condition MeSH

Condition MeSH for Mdp-bracco
Intervention	Trials
Myocardial Infarction	3
Infarction	3
Heart Failure	1
Brain Ischemia	1

Clinical Trial Locations for Mdp-bracco

Trials by Country

Trials by Country for Mdp-bracco
Location	Trials
United States	10
Italy	2
Germany	1
Netherlands	1
Belgium	1

Trials by US State

Trials by US State for Mdp-bracco
Location	Trials
Pennsylvania	4
North Carolina	1
Massachusetts	1
Illinois	1
Arizona	1

Clinical Trial Progress for Mdp-bracco

Clinical Trial Phase

Clinical Trial Phase for Mdp-bracco
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	4
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for Mdp-bracco
Clinical Trial Phase	Trials
Completed	4
Recruiting	4
Terminated	2

Clinical Trial Sponsors for Mdp-bracco

Sponsor Name

Sponsor Name for Mdp-bracco
Sponsor	Trials
Children's Hospital of Philadelphia	3
Catholic University of the Sacred Heart	2
Bracco Diagnostics, Inc	2

Sponsor Type

Sponsor Type for Mdp-bracco
Sponsor	Trials
Other	22
Industry	4